Welcome to our dedicated page for Ross Acquisition II news (Ticker: ROSS), a resource for investors and traders seeking the latest updates and insights on Ross Acquisition II stock.
Ross Acquisition Corp II (NYSE: ROSS) is a special purpose acquisition company (SPAC) established to facilitate mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or other similar business combinations with one or more enterprises. Founded by Ross Holding Company LLC and affiliated with prominent figures such as Wilbur L. Ross, Stephen J. Toy, and Nadim Z. Qureshi, the company successfully completed its initial public offering (IPO) in March 2021.
Recently, on September 1, 2023, Ross Acquisition Corp II filed a definitive proxy statement to solicit proxies for an extraordinary general meeting to extend the deadline for consummating a business combination from September 16, 2023, to March 16, 2024. This proposal, known as the Extension Amendment Proposal, is crucial for the company's future operations. If this proposal is not approved, the company plans to cease operations, redeem all Class A ordinary shares sold during the IPO, and liquidate and dissolve the company.
The company’s primary objective is to capitalize on the extensive network and industry expertise of its sponsors to identify and merge with a high-potential business. The current focus is to secure shareholder approval for the Extension Amendment Proposal to ensure the company has ample time to complete its initial business combination. This strategic move could significantly impact shareholder value and the company’s future trajectory.
Ross Acquisition Corp II is committed to transparent and regular communication with its shareholders. The company encourages its shareholders and interested parties to read the definitive proxy statement and other documents filed with the SEC as these documents contain vital information. These can be accessed free of charge at www.sec.gov.
For more details, shareholders are advised to contact Ross Acquisition Corp II's representatives via the contact information provided at the company's official address in Palm Beach, Florida.
ROSS Acquisition Corp II (NYSE: ROSS,WS) has entered into a definitive agreement to merge with APRINOIA Therapeutics, a clinical-stage biotech focused on neurodegenerative diseases. The transaction is valued at $280 million, with funding aimed at advancing APRINOIA's therapeutic programs, including its lead product, APN-1607. The merger, expected to close in the first half of 2023, will create a publicly traded entity on Nasdaq or NYSE. APRINOIA holds agreements with major biotech firms such as Biogen, and anticipates significant market opportunities in treating Alzheimer’s Disease, which affects an estimated 10 million individuals in China alone.
On May 27, 2021, Ross Acquisition Corp II (NYSE: ROSS) announced it regained compliance with NYSE regulations after filing its Form 10-Q for the quarter ended March 31, 2021. This filing came after receiving a notice from the NYSE on May 25, 2021, indicating non-compliance due to a delayed filing. The NYSE gave the company six months to rectify the issue. The compliance reinstatement means the listing of ROSS on the NYSE remains unaffected.
FAQ
What is the market cap of Ross Acquisition II (ROSS)?
What is Ross Acquisition Corp II?
When was Ross Acquisition Corp II's IPO?
What is the Extension Amendment Proposal?
What happens if the Extension Amendment Proposal is not approved?
How can shareholders participate in the upcoming extraordinary general meeting?
Where can I find the definitive proxy statement?
Who are the sponsors of Ross Acquisition Corp II?
What are the risks associated with Ross Acquisition Corp II?
How does Ross Acquisition Corp II plan to inform its shareholders?
What happens to the public shares if the company liquidates?
